PDX Portal

Model Details

Patient Information for Model: BCM-15171

Model Contact

Model: BCM-15171
Model Contact: Michael Lewis
Institution: BCM Breast PDX Program
Email: mtlewis@bcm.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-15171

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

PDX Validation

In order to validate the identity of Baylor College of Medicine patient-derived xenograft (PDX) models, short tandem repeat (STR) testing is performed at the Cytogenetics and Cell Authentication core facility at MDACC. STR testing is performed on tissue from the initial tumor grown in the mouse (transplant generation 1 - TG1) and from a patient sample when possible. Thereafter, STR testing is performed every five transplant generations (TG5, TG10, TG15, and TG20). In the case that a PDX model is transplanted from viably frozen tissue to restart the model, the PDX Core will test the first outgrowth to confirm identity and every five transplant generations thereafter. In addition to STR, we assess clinical biomarkers and histology every 5th transplant generation. Finally, RNAseq gene expression profiles are evaluated periodically to ensure consistency with previous results and to evaluate phenotypic drift. If a significant change in PDX biology is noted, we identify the last known stable stock and re-start the model.

Histology Information for Model: BCM-15171

There are no histology images for this model.

Metastasis Information for Model: BCM-15171

Patient

PDX

Abdomen

Adrenal gland

Bone

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

Liver

Lung

Lymph node

Lymph nodes

Neck

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

Patient Treatment Information for Model: BCM-15171

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
15	Docetaxel,Pertuzumab,Trastuzumab	Metastatic	30.23	33.64	1245 days	Stable Disease	Not Applicable	Disease Progression
30	Ado-Trastuzumab Emtansine,Trastuzumab	Metastatic	33.72	35.95	814 days	Progressive Disease	Not Applicable	Side Effects
45	Trastuzumab	Metastatic	36.11	36.29	66 days	Stable Disease	Not Applicable	Disease Progression
55	Paclitaxel	Metastatic	36.49	36.8	113 days	Not Reported	Not Applicable	Treatment Completed
60	Radiation Therapy	Metastatic	36.53	36.56	11 days	Not Reported	Not Applicable	Treatment Completed
70	Radiation Therapy	Metastatic	36.8	36.83	11 days	Partial Response	Not Applicable	Treatment Completed
75	Capecitabine,Trastuzumab	Metastatic	36.84	37.85	369 days	Progressive Disease	Not Applicable	Unknown
90	Radiation Therapy	Metastatic	37.33	37.33	1	Not Reported	Not Applicable
95	Radiation Therapy	Metastatic	37.67	37.68	4 days	Progressive Disease	Not Applicable	Treatment Completed
100	Fam-trastuzumab deruxtecan-nxki	Metastatic	37.85	37.97	44 days	Progressive Disease	Not Applicable	Treatment Completed